[go: up one dir, main page]

WO2002003977A3 - Combinations of statins, estrogenic agents and optionally estrogens - Google Patents

Combinations of statins, estrogenic agents and optionally estrogens Download PDF

Info

Publication number
WO2002003977A3
WO2002003977A3 PCT/US2001/021085 US0121085W WO0203977A3 WO 2002003977 A3 WO2002003977 A3 WO 2002003977A3 US 0121085 W US0121085 W US 0121085W WO 0203977 A3 WO0203977 A3 WO 0203977A3
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
ethers
statins
combinations
esters
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2001/021085
Other languages
French (fr)
Other versions
WO2002003977A2 (en
Inventor
Simon Nicholas Jenkins
Barry Samuel Komm
Christopher Paul Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth LLC filed Critical Wyeth LLC
Priority to BR0112365-3A priority Critical patent/BR0112365A/en
Priority to JP2002508432A priority patent/JP2004502731A/en
Priority to EP01950826A priority patent/EP1359940A2/en
Priority to MXPA02012896A priority patent/MXPA02012896A/en
Priority to CA002414060A priority patent/CA2414060A1/en
Priority to AU2001271785A priority patent/AU2001271785A1/en
Publication of WO2002003977A2 publication Critical patent/WO2002003977A2/en
Anticipated expiration legal-status Critical
Publication of WO2002003977A3 publication Critical patent/WO2002003977A3/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

This invention comprises methods of treating cardiovascular disorders and lowering blood LDL levels comprising administration of a statin, an estrogen and compound of the formulae (I or II): wherein Z is a moiety selected from the group of: (III) wherein: R1 is selected from H, OH or the C1-C12 esters or C1-C12 alkyl ethers thereof, benzyloxy, or halogen; or C1-C4 halogenated ethers including trifluoromethyl ether and trichloromethyl ether; R2, R3, R4, R5, and R6 are H, OH or C1-C12 esters or C1-C12 alkyl ethers thereof, halogens, or C1-C4 halogenated ethers, cyano, C1-C6 alkyl, or trifluoromethyl, with the proviso that, when R1 is H1, R2 is not OH; Y is the moiety: (IV) R7 and R8 are alkyl or concatenated together to form an optionally substituted, nitrogen-containing ring; or a pharmaceutically acceptable salt thereof.
PCT/US2001/021085 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens Ceased WO2002003977A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
BR0112365-3A BR0112365A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogens and optionally estrogens
JP2002508432A JP2004502731A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogens and optional estrogens
EP01950826A EP1359940A2 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens
MXPA02012896A MXPA02012896A (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens.
CA002414060A CA2414060A1 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens
AU2001271785A AU2001271785A1 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US21609600P 2000-07-06 2000-07-06
US21618400P 2000-07-06 2000-07-06
US60/216,184 2000-07-06
US60/216,096 2000-07-06

Publications (2)

Publication Number Publication Date
WO2002003977A2 WO2002003977A2 (en) 2002-01-17
WO2002003977A3 true WO2002003977A3 (en) 2003-09-04

Family

ID=26910656

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/021085 Ceased WO2002003977A2 (en) 2000-07-06 2001-06-29 Combinations of statins, estrogenic agents and optionally estrogens

Country Status (8)

Country Link
EP (1) EP1359940A2 (en)
JP (1) JP2004502731A (en)
CN (1) CN1468110A (en)
AU (1) AU2001271785A1 (en)
BR (1) BR0112365A (en)
CA (1) CA2414060A1 (en)
MX (1) MXPA02012896A (en)
WO (1) WO2002003977A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004039327A2 (en) 2002-10-29 2004-05-13 Colorado State University Research Foundation Use of equol for treating androgen mediated diseases
US8668914B2 (en) 2002-07-24 2014-03-11 Brigham Young University Use of equol for treating skin diseases
AU2003259220C1 (en) 2002-07-24 2017-08-24 Australian Health & Nutrition Association Limited Compositions and products containing enantiomeric equol, and methods for their making
US8580846B2 (en) 2002-10-29 2013-11-12 Brigham Young University Use of equol for ameliorating or preventing neuropsychiatric and neurodegenerative diseases or disorders
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
SMT202100433T1 (en) 2015-10-01 2021-09-14 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indole anti-estrogenic drugs
HRP20221462T1 (en) 2015-12-09 2023-01-20 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
CN120887906A (en) 2016-05-10 2025-11-04 C4医药公司 Spirocyclic degradation determinant for target protein degradation
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR THE DEGRADATION OF TARGET PROTEINS
ES2989988T3 (en) 2016-05-10 2024-11-28 C4 Therapeutics Inc Heterocyclic degronimers for the degradation of target proteins
MX2019000200A (en) 2016-07-01 2019-09-26 G1 Therapeutics Inc Pyrimidine-based antiproliferative agents.
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
AU2018205262A1 (en) 2017-01-06 2019-07-11 G1 Therapeutics, Inc. Combination therapy for the treatment of cancer
JP2020507566A (en) 2017-02-10 2020-03-12 ジー１ セラピューティクス， インコーポレイテッド Benzothiophene estrogen receptor modulator
CN110769822A (en) 2017-06-20 2020-02-07 C4医药公司 N/O-linked degron and degron bodies for protein degradation
MX392531B (en) 2017-06-29 2025-03-24 G1 Therapeutics Inc MORPHIC FORMS OF G1T38 AND METHODS OF PREPARING THE SAME.
CN113453679B (en) 2018-12-20 2025-07-08 C4医药公司 Targeted protein degradation
CN114302722A (en) 2019-07-07 2022-04-08 奥列马制药公司 Estrogen receptor antagonist regimens
PE20221724A1 (en) 2019-12-20 2022-11-04 C4 Therapeutics Inc ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) DEGRADATION
AU2021231898A1 (en) 2020-03-05 2022-10-27 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
EP4192458A4 (en) 2020-08-05 2024-09-04 C4 Therapeutics, Inc. COMPOUNDS FOR TARGETED RET DEGRADATION
EP4565585A1 (en) 2022-08-03 2025-06-11 Bristol-Myers Squibb Company Compounds for modulating ret protein
EP4611900A1 (en) 2022-11-04 2025-09-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
KR20250117789A (en) 2022-11-04 2025-08-05 브리스톨-마이어스 스큅 컴퍼니 RET-LDD protein degrader
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059969A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation Compositions comprising 2-phenyl-indole compounds and estrogen formulations
WO1999059581A1 (en) * 1998-05-15 1999-11-25 American Home Products Corporation 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole in combination with estrogens

Also Published As

Publication number Publication date
MXPA02012896A (en) 2003-10-24
AU2001271785A1 (en) 2002-01-21
CN1468110A (en) 2004-01-14
EP1359940A2 (en) 2003-11-12
WO2002003977A2 (en) 2002-01-17
CA2414060A1 (en) 2002-01-17
BR0112365A (en) 2003-05-13
JP2004502731A (en) 2004-01-29

Similar Documents

Publication Publication Date Title
WO2002003977A3 (en) Combinations of statins, estrogenic agents and optionally estrogens
WO2002003976A3 (en) Combinations of bisphosphonates, estrogenic agents and optionally estrogens
WO2002003992A3 (en) Use of substituted indole compounds for treating prosthesis-related bone degeneration
WO2002003986A3 (en) Use of substituted indole compounds for treating breast disorders
WO2002003988A3 (en) Use of substituted indole compounds for treating neuropeptide y-related conditions
WO2002003990A3 (en) Use of substituted insole compounds for treating excessive intraocular pressure
WO2002003989A3 (en) Use of substituted indole compounds for treating sphincter incontinence
WO2002003991A3 (en) Use of substituted indole compounds for increasing nitric oxide synthase activity
WO2002004418A3 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
WO2002003987A3 (en) Pharmaceutical compositions of estrogenic agents
HRP20000726B1 (en) DERIVATI QUINOLINA
IL105421A0 (en) Taxol derivatives
EP1040823A3 (en) Stable foam compositions
WO2001009103A3 (en) Imidazole antiproliferative agents
DK1299348T3 (en) Compounds and compositions for delivery of active agents
YU1501A (en) Quinoline derivatives
MX9700883A (en) Substituted quinazoline derivatives.
MXPA04004674A (en) Cannabinoid receptor ligands.
WO2000066614A8 (en) 3α-HYDROXY-3β METHOXYMETHYL-21-HETEROCYCLE SUBSTITUTED STEROIDS WITH ANESTHETIC ACTIVITY
CA2313122A1 (en) Bicycliccarbonyl indole compounds as anti-inflammatory/analgesic agents
EP0700291A4 (en) 4-SUBSTITUTED AZASTEROIDS IN POSITION 15
EP1277744A4 (en) Oxadiazole derivatives having anticancer effects
KR20000005379A (en) Isatin derivatives as acetylcholinesterase inhibitors and analgesics
CA2302943A1 (en) Phthalazine compounds and therapeutic agents for erectile dysfunction
WO2001005386A3 (en) Pharmaceutical composition useful for the treatment of tinnitus and hearing loss

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012896

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2001950826

Country of ref document: EP

Ref document number: 2414060

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 018150896

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2001950826

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001950826

Country of ref document: EP